

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A procoagulant-active FVIII protein comprising a human FVIII polypeptide that is modified, wherein the modification comprises a substitution of the Phe309 with Ser. ~~mutation at Phe309.~~

2-7. **(Cancelled)**

8. **(Original)** A pharmaceutical composition comprising an effective amount of the protein of Claim 1 in admixture with a parenterally acceptable vehicle or excipient.

9-10. **(Cancelled)**

11. **(Currently Amended)** A procoagulant-active FVIII protein comprising a human FVIII polypeptide that is modified, wherein the modification comprises a substitution of the Arg residue at position 336 with Ile and a substitution of the Arg residue at position 562 with Lys ~~The protein of Claim 10,~~ wherein the modification further comprises a mutation at position 309 Phe309, and wherein said protein is APC resistant.

12. **(Cancelled)**

13. **(Currently Amended)** A pharmaceutical composition comprising an effective amount of the protein of Claim ~~10~~ 11 in admixture with a parenterally acceptable vehicle or excipient.

14-40. **(Cancelled)**

41. **(New)** A pharmaceutical composition comprising an effective amount of the protein of Claim 11 in admixture with a parenterally acceptable vehicle or excipient.

42. **(New)** The protein of claim 11, wherein said protein is capable of increased secretion.